Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
haNK for Infusion · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1, 2x10^9 Cells haNK™ | EXPERIMENTAL | NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous Infusion |
| Name | Type | Description |
|---|---|---|
| haNK™ for Infusion | BIOLOGICAL | haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a). |
Inclusion Criteria: 1. Age ≥ 18 years old. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines. 3. Histologically confirmed, unresectable, locally advanced or metastatic solid malignancy. 4. ECOG performance status of 0 to 2. 5. Have at least...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
haNK for Infusion is an investigational therapy being studied for the treatment of metastatic or locally advanced solid tumors. It is a monoclonal antibody-based treatment in clinical development for oncology indications.
haNK for Infusion is being developed by ImmunityBio, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol IBRX. The company is conducting clinical research to evaluate the therapy in patients with solid tumors.
haNK for Infusion is in Phase 1 clinical development. It is an investigational agent and has not been approved by regulatory authorities. The therapy is being evaluated for safety and tolerability in patients with advanced solid tumors.
haNK for Infusion has been studied in clinical trial NCT03027128, titled QUILT-3.028: Study of haNK for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors. This Phase 1 trial was conducted in the United States and has been completed.
haNK for Infusion is a monoclonal antibody-based therapy. It is designed to target and engage the immune system to fight cancer cells. The specific molecular target of haNK for Infusion has not been disclosed in available clinical trial information.